DUBLIN, Nov. 6, 2019 -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-Care ProductsTM", today announced financial results for the third quarter ended September 28, 2019.
Perrigo scientists gave a ‘big’ science lesson to West Michigan families when they unveiled the world’s largest periodic table on Saturday. Officials from the Guinness Book of World Records were present to judge the feat.
Perrigo Company plc (NYSE; TASE: PRGO) announced that its “Quitting is Better” nicotine replacement therapy campaign has earned national recognition from the Consumer Healthcare Products Association (CHPA) Educational Foundation for innovation and strategic marketing in the consumer healthcare products industry.
Upon receiving communication from the U.S. Food and Drug Administration (FDA) regarding the potential for presence of N-nitrosodimethylamine (NDMA) in certain ranitidine-based products, Perrigo Company plc promptly initiated testing of its externally sourced ranitidine API and ranitidine-based products.
The Perrigo Charitable Foundation and Perrigo employees have joined together to help victims of Hurricane Dorian both within the U.S. and internationally. Hurricane Dorian impacted multiple southeast states, the Caribbean, and the Bahamas as it made landfall last week.
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has entered into a definitive agreement to acquire the branded OTC rights to Prevacid® from GlaxoSmithKline.
DUBLIN, Ireland and Allegan, Michigan – July 15, 2019 --The Perrigo Company Charitable Foundation is proud to announce a donation of $50,000 to the Saugatuck Center for the Arts (SCA) which will support an entire year of arts education programming throughout the tri-county areas of Allegan, Kent, and Ottawa Counties.
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (NASDAQ: PETQ) for $185 million.
Perrigo Company plc (NYSE; TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug Application (“ANDA”) referencing Metrogel-Vaginal® (metronidazole vaginal gel 0.75%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days and anticipates launching this product immediately thereafter.
Perrigo Company plc (NYSE; TASE: PRGO) today announced the successful completion of its acquisition of Ranir Global Holdings LLC ("Ranir"), the leading global store brand supplier of oral self-care products, for $750 million in cash. This transaction advances Perrigo's transformation to a consumer-focused, self-care company while enhancing its position as a global leader in consumer self-care solutions.